FDA panel endorses first-of-a-kind cancer blood test from Grail
A company called Grail developed a blood test called Galleri that can detect signs of multiple cancers in people who appear healthy. The test costs $949 and was reviewed by advisers to the U.S. Food and Drug Administration. An FDA panel backed the test, though concerns remain that positive results might lead patients to get unnecessary scans and biopsies without confirming actual disease.
13 across the spectrum · tap a section to jump
The story so far
2 developments- Sep 23Grail's cancer blood test faces high-stakes FDA review
- Sep 24FDA advisory panel endorsed Grail's multi-cancer blood test in a split vote
Who covered each development
No new developments
Quiet for 5 daysLast development · Sep 24 — FDA advisory panel endorsed Grail's multi-cancer blood test in a split vote
Left
4 viewpointsA Controversial Cancer-Detecting Blood Test Just Got Backed by Key FDA Panel
Blood test for multiple cancers clears crucial hurdle on track to FDA approval
FDA panel endorses first-of-a-kind cancer blood test from Grail
FDA advisers are voting on Grail's multicancer blood test as Medicare coverage hangs in the balance
Center
8 viewpointsThis Controversial Cancer Test Just Passed a Key FDA Vote. Here’s Why It’s Dividing Experts
One blood test could screen you for 50 cancers. Here’s why it’s controversial.
Right
1 viewpointGrail Surges After FDA Advisors Back Its Cancer-Finding Blood Test
FDA panel endorses first-of-a-kind cancer blood test from Grail
Grail’s cancer blood test faces high-stakes FDA review